Search Within

John Frank Gerecitano

Formats
  1. Meeting Abstract (100)
  2. Journal Article (51)
  3. Book Section (1)
  4. Book Whole (1)
Groups
  1. Department of Medicine (153)
  2. Hematologic Malignancies, Division of (153)
  3. Center for Hematologic Malignancies (82)
  4. Lymphoma (75)
  5. Survivorship Research (56)
  6. Executive Committee, Center for Hematologic Malignancies (45)

More Groups

People
  1. Andrew Zelenetz (62)
  2. Paul Hamlin (60)
  3. Craig Moskowitz (57)
  4. David Straus (56)
  5. Ariela Noy (50)
  6. Matthew Matasar (48)

More People

Years
  1. 2024 (1)
  2. 2022 (3)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (8)

More Years

Publications
  1. Blood (45)
  2. Journal of Clinical Oncology (34)
  3. Haematologica (11)
  4. Clinical Cancer Research (9)
  5. Hematological Oncology (8)
  6. Annals of Oncology (7)

More Publications

Publishers
  1. American Society of Hematology (46)
  2. American Society of Clinical Oncology (34)
  3. American Association for Cancer Research (11)
  4. Ferrata Storti Foundation (11)
  5. Wiley Blackwell (10)
  6. Oxford University Press (7)

More Publishers

Results (153)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sequential RCHOP and yttrium-90 ibritumomab tiuxetan (RIT) is a highly effective regimen for high risk elderly patients with untreated DLBCL
    Meeting Abstract

    Hamlin, P. A.; Moskowitz, C. H.; Wegner, B.; Noy, A.; Gerecitano, J.; Palomba, M. L.; Portlock, C.; Straus, D.; Pro, B.; Fayad, L.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • Bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P): Two dosing schedules of a novel phase I regimen in patients with relapsed/refractory indolent and mantle cell lymphomas
    Meeting Abstract

    Gerecitano, J.; Portlock, C.; Hamlin, P.; Moskowitz, C.; Noy, A.; Straus, D.; Zelenetz, A. D.; Schulman, P.; Dumitrescu, O.; O'Connor, O. A.
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • A phase I/II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 administered on days I and 15 every 28 days without and with prophylactic G-CSF in non-Hodgkin or Hodgkin lymphoma
    Meeting Abstract

    Gerecitano, J.; O'connor, O.; Van Deventer, H.; Hainsworth, J.; Leonard, J.; Goy, A.; Afanasyev, B.; Chen, M.; Saikali, K.; Conlan, M. G.; more...
    Blood (2008)

    Fulltext@MSK | Save
  • Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: Phase I results
    Meeting Abstract

    Orlowski, R. Z.; Stewart, K.; Vallone, M.; Molineaux, C.; Kunkel, L.; Gerecitano, J.; O'Connor, O. A.
    Blood (2007)

    Fulltext@MSK | Save
  • Pre-treatment p27 and Bcl-6 staining levels correlate with response to bortezomib in non-Hodgkin lymphoma: Results from a tissue microarray analysis
    Meeting Abstract

    Gerecitano, J.; Gounder, S.; Feldstein, J.; Ogilvie, S.; Lin, D.; Zheng, J.; Zhang, Z.; McDonald, A.; Mulligan, G.; O'Connor, O. A.
    Blood (2007)

    Fulltext@MSK | Save
  • Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-Cell lymphomas: Results of the MSKCC phase I/II experience
    Meeting Abstract

    O'Connor, O. A.; Hamlin, P. A.; Gerecitano, J.; Portlock, C. S.; Noy, A.; Moskowitz, C.; Straus, D. J.; Sarasohn, D.; Dumitrescu, O.; Pappanicholaou, J.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders
    Meeting Abstract

    Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • Treatment of Burkitt lymphoma in adults
    Journal Article

    Gerecitano, J.; Straus, D. J.
    Expert Review of Anticancer Therapy (2006)

    Fulltext@MSK | Save
  • Novel small molecules in the treatment of lymphomas
    Journal Article

    Gerecitano, J.; O'Connor, O. A.
    Cancer Treatment and Research (2006)

    Fulltext@MSK | Save
  • Drug-induced cutaneous vasculitis in patients with non-Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: A possible surrogate marker of response?
    Journal Article

    Gerecitano, J.; Goy, A.; Wright, J.; Macgregor-Cortelli, B.; Neylon, E.; Gonen, M.; Esseltine, D.; Boral, A.; Schenkein, D.; Busam, K.; more...
    British Journal of Haematology (2006)

    Fulltext@MSK | Save